Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R0.6C malaria transmission-blocking vaccine study with Alhydrogel with or without Matrix-M in healthy adults
NL-OMON51178Completed
- Sponsor
- Radboud University Medical Center
- Start
- May 2021
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label trial of R0.6C vaccine, aluminium hydroxide and Matrix M in malaria and Falciparum malaria (PF) (8 arms), sponsored by Radboud University Medical Center. Primary endpoints: Primary safety endpoint and Primary efficacy endpoint. Started May 2021; status: completed.
02
Drugs
R0.6C vaccinealuminium hydroxideMatrix M
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on NL-OMON51178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51178.